Citations

Mayo Clinic

Showing 10 of 108602 citations.

Unknown Causes of Death in Cancer Patients
Chinniah, Siven, Chiam, Mckenzee , Mani, Kyle , Liang, Menglu , Prasad, Vinayak K., Zaorsky, Nicholas G , Trifiletti, Daniel M. , Spratt, Daniel E. , Wang, Ming , Tchelebi, Leila T. , Zaorsky, Nicholas G.

American Journal of Clinical Oncology | April 11, 2023 | Volume: 46 | Issue: 6 | Pages: 246-253

10.1097/coc.0000000000001003 | PMID 37038261 Get It

Objectives: Deaths from an unknown cause are difficult to adjudicate and oncologic studies of comparative effectiveness often demonstrate inconsistencies in incorporating these deaths and competing events (eg, heart disease and stroke) in their analyses. In this study, we identify cancer patients most at risk for death of an unknown cause. Methods: This retrospective, population-based study used cancer registry data from the Surveillance, Epidemiology, and End Results database (1992-2015). The absolute rate of unknown causes of death (COD) cases stratified by sex, marital status, race, treatment, and cancer site were calculated and a multivariable logistic regression model was applied to obtain adjusted odds ratios with 95% CIs. Results: Out of 7,154,779 cancer patients across 22 cancer subtypes extracted from Surveillance, Epidemiology, and End Results, 3,448,927 died during follow-up and 276,068 (7.4%) of these deaths were from unknown causes. Patients with an unknown COD had a shorter mean survival time compared with patients with known COD (36.3 vs 65.7 mo, P < 0.001). The contribution of unknown COD to total mortality was highest in patients with more indolent cancers (eg, prostate [12.7%], thyroid [12.3%], breast [10.7%]) and longer follow-up (eg, >5 to 10 y). One, 3, and 5-year cancer-specific survival (CSS) calculations including unknown COD were significantly decreased compared with CSS estimates excluding cancer patients with unknown COD. Conclusion: Of the patients, 7.4% died of unknown causes during follow-up and the proportion of death was higher with longer follow-up and among more indolent cancers. The attribution of high percentages of unknown COD to cancer or non-cancer causes could impact population-based cancer registry studies or clinical trial outcomes with respect to measures involving CSS and mortality.
Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy
Zand, Ladan , Fervenza, Fernando C. , Fervenza, Fernando C

Clinical Kidney Journal | April 11, 2023 | Volume: 16 | Issue: 9 | Pages: 1420-1425

10.1093/ckj/sfad075 | PMID 37669312 Get It

ABSTRACT Membranous nephropathy (MN) is a common cause of nephrotic syndrome (NS) in adults and if untreated can progress to endstage kidney disease. Factors considered to place a patient at high or very high risk for progression include elevated serum creatinine at baseline, declining kidney function, persistent heavy proteinuria (&gt;8 g/24 h), or persistent NS, presence of life-threatening complications related to NS (such as venous thromboembolic events), or very high anti-PLA2R antibody titers (&gt;150 RU/ml). Patients who are at high or very high risk of progression should be treated with immunosuppression therapy to induce remission of proteinuria and to avoid progressive loss of kidney function. Traditional forms of immunosuppression for patients with MN have included the use of cyclic courses of corticosteroids with cyclophosphamide or calcineurin inhibitors. These forms of therapy are associated with significant toxicity, e.g. corticosteroids (infections, diabetes, weight gain), cyclophosphamide (infertility, severe leukopenia, malignancy), and calcineurin inhibitors (hypertension, nephrotoxicity). The introduction of anti-CD20+ B-cell therapies in the late 1990s has changed the landscape. In this article we will argue that anti-CD20+ B therapy should be the treatment of choice for patients at high/very high risk of progression when considering its efficacy and side-effect profile.
Particle Thompson Sampling with Static Particles
Zhou, Zeyu , Hajek, Bruce

2023 57th Annual Conference on Information Sciences and Systems (CISS) | April 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/ciss56502.2023.10089653 Get It

Improving Particle Thompson Sampling through Regenerative Particles
Zhou, Zeyu , Hajek, Bruce

2023 57th Annual Conference on Information Sciences and Systems (CISS) | April 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/ciss56502.2023.10089647 Get It

Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction.
Redgrave, Rachael E. , Dookun, Emily , Booth, Laura , Folaranm, Omowumi, Tual‐Chalot, Simon , Passos, João F. , Richardson, Gavin D. , Passos, Joao, Richardson, Gavin D , Passos, João F , Gill, Jason H. , Owens, W. Andrew , Spyridopoulos, Ioakim

No container title available | April 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2776501/v1 | PMID 37090497 Get It

Abstract Myocardial infarction is a leading cause of morbidity and mortality. While reperfusion is now standard therapy, pathological remodeling leading to heart failure remains a clinical problem. Cellular senescence has been shown to contribute to disease pathophysiology and treatment with the senolytic navitoclax attenuates inflammation, reduces adverse myocardial remodeling and results in improved functional recovery. However, it remains unclear which senescent cell populations contribute to these processes. To identify whether senescent cardiomyocytes contribute to disease pathophysiology post-myocardial infarction, we established a transgenic model in which p16 (CDKN2A) expression was specifically knocked-out in the cardiomyocyte population. Following myocardial infarction, mice lacking cardiomyocyte p16 expression demonstrated no difference in cardiomyocyte hypertrophy but exhibited improved cardiac function and significantly reduced scar size in comparison to control animals. This data demonstrates that senescent cardiomyocytes participate in pathological myocardial remodeling. Importantly, inhibition of cardiomyocyte senescence led to reduced senescence-associated inflammation and decreased senescence-associated markers within other myocardial lineages, consistent with the hypothesis that cardiomyocytes promote pathological remodeling by spreading senescence to other cell-types. Collectively this study presents a novel demonstration that senescent cardiomyocytes are major contributors to myocardial remodeling and dysfunction following a myocardial infarction. Therefore, to maximize the potential for clinical translation, it is important to further understand the mechanisms underlying cardiomyocyte senescence and how to optimize senolytic strategies to target this cell lineage.
Utility of a Smartphone Application in Assessing Palmar Circulation Before Radial Artery Harvesting for Coronary Artery Bypass Grafting
Parlow, Simon , Santo, Pietro Di , Abdel‐Razek, Omar , Jung, Richard G. , Motazedian, Pouya , Feagan, Hannah, Morgan, Baylie , Wade, Jilliane, Toeg, Hadi , Al‐Atassi, Talal , Kuhar, Peter , Bernick, Jordan , Wells, George A. , Froeschl, Michael , Mathew, Rebecca , Labinaz, Marino , Hibbert, Benjamin , Hibbert, Benjamin , Robinson, Lisa, Ruel, Marc , Simard, Trevor , Marbach, Jeffrey A. , Chan, Vincent

Circulation | April 10, 2023 | Volume: 147 | Issue: 15 | Pages: 1183-1185

10.1161/circulationaha.122.063795 | PMID 37036908 Get It

“Not All That Fistulizes Is Crohn's Disease”: A Rare Case of Ischemic Jejunocolic Fistula
Gala, Khushboo , Ghusn, Wissam , Chedid, Victor , Ghusn, Wissam , Chedid, Victor G

ACG Case Reports Journal | April 10, 2023 | Volume: 10 | Issue: 4 | Pages: e01021

10.14309/crj.0000000000001021 | PMID 37057193 Get It

ABSTRACT Enterocolic fistulae lead to abnormal diversion of gastrointestinal contents from the small intestine to the colon, causing diarrhea and protein energy malnutrition. We describe a rare case of a 40-year-old patient presenting with chronic diarrhea, unintentional weight loss, sitophobia, and severe abdominal pain in the setting of extensive thrombosis due to JAK2 V617F mutant disorder and associated tobacco use. Computed tomography enterography demonstrated an enterocolic fistula (jejunum to cecum), and a colonoscopy confirmed a 4 mm fistula in the cecum. The patient was nutritionally optimized with plans for a surgical fistula takedown in the future.
CHANGES IN VASOACTIVE DRUG REQUIREMENTS AND MORTALITY IN CARDIAC INTENSIVE CARE UNIT PATIENTS
Patel, Parag C. , Barsness, Gregory W. , Jentzer, Jacob C. , Diepen, Sean van , Morrow, David A. , Kashani, Kianoush

Shock | April 10, 2023 | Volume: 59 | Issue: 6 | Pages: 864-870

10.1097/shk.0000000000002123 | PMID 37037002 Get It

ABSTRACT Background: The Society for Cardiovascular Angiography and Intervention (SCAI) Shock Classification can define shock severity. We evaluated the vasoactive-inotropic score (VIS) combined with the SCAI Shock Classification for mortality risk stratification. Methods: This was a single-center retrospective cohort analysis including Mayo Clinic cardiac intensive care unit patients from 2007 to 2015. The peak VIS was calculated at 1 and 24 h after cardiac intensive care unit admission. In-hospital mortality was evaluated using multivariable logistic regression. Results: Of 9,916 included patients, vasoactive drugs were used in 875 (8.8%) within 1 h and 2,196 (22.1%) within 24 h. A total of 888 patients (9.0%) died during hospitalization. Patients who required vasoactive drugs within 1 h had higher in-hospital mortality (adjusted odds ratio [OR], 1.30; 95% confidence interval [CI], 1.03–1.65; P = 0.03) and in-hospital mortality rose with the VIS during the first 1 h (adjusted OR per 10 units, 1.22; 95% CI, 1.12–1.33; P < 0.001). The increase in VIS from 1 to 24 h was associated with higher in-hospital mortality (adjusted OR per 10 units, 1.16; 95% CI, 1.10–1.21; P < 0.001). These results were consistent in the 1,067 patients (10.9%) with cardiogenic shock. A gradient of in-hospital mortality was observed according to the VIS at 1 h and the increase in VIS from 1 to 24 h. Conclusions: Higher vasoactive drug requirements portend a higher risk of mortality, particularly a high VIS early after admission. The VIS provides incremental prognostic information beyond the SCAI Shock Classification, emphasizing the continuum of risk that exists across the spectrum of shock severity.
STAT2 hinders STING intracellular trafficking and reshapes its activation in response to DNA damage
Wang, Chenyao , Holvey-Bates, Elise, Wightman, Samantha M. , Latif, Muhammad-Bilal, Zhao, Junjie , Li, Xiaoxia , Sen, Ganes C. , Stark, George R. , Wang, Yuxin , Wightman, Samantha , Sen, Ganes C , Stark, George R , Wang, Yuxin , Jing, Nan , Chen, Xing

Proceedings of the National Academy of Sciences | April 10, 2023 | Volume: 120 | Issue: 16 | Pages: No page available

10.1073/pnas.2216953120 | PMID 37036972 Get It

In cancer cells, endogenous or therapy-induced DNA damage leads to the abnormal presence of DNA in the cytoplasm, which triggers the activation of cGAS (cyclic GMP–AMP synthase) and STING (stimulator of interferon genes). STAT2 suppresses the cGAMP-induced expression of IRF3-dependent genes by binding to STING, blocking its intracellular trafficking, which is essential for the full response to STING activation. STAT2 reshapes STING signaling by inhibiting the induction of IRF3-dependent, but not NF-κB–dependent genes. This noncanonical activity of STAT2 is regulated independently of its tyrosine phosphorylation but does depend on the phosphorylation of threonine 404, which promotes the formation of a STAT2:STING complex that keeps STING bound to the endoplasmic reticulum (ER) and increases resistance to DNA damage. We conclude that STAT2 is a key negative intracellular regulator of STING, a function that is quite distinct from its function as a transcription factor.
Racial Disparities in Treatment Initiation and Outcomes of Chronic Hepatitis B Virus Infection in North America
Khalili, Mandana , Leonard, Kelsey R., Roberts, Lewis R. , Sterling, Richard K. , Belle, Steven H., Lau, Daryl , Chung, Raymond , Bisceglie, Adrian M. Di , Lisker‐Melman, Mauricio , Juan, Joshua, Yim, Colina, Lee, William M. , Murakam, Carol S., Perrillo, Robert, Do, Son , Han, Steven‐Huy B. , Tran, Tram T. , Cooper, Stewart , Tsai, Naoky, Younoszai, Barak, Fried, Michael, Darling, Jama M., Carithers, Robert C., Shuhart, Margaret C., Wang, Chia C. , Luketic, Velimir A. , Hoofnagle, Jay H., Doo, Edward , Park, Jang‐June , Roberts, Lewis R , Khalili, Mandana , Ghany, Marc G. , Hassan, Mohamed Ahmed Salih , Lok, Anna S. , Janssen, Harry L.A. , Wong, David , Feld, Jordan J. , Terrault, Norah A. , Fontana, Robert J. , Muir, Andrew Joseph , Evon, Donna M. , Kowdley, Kris V. , Liang, T. Jake , Chang, Kyong‐Mi , Wahed, Abdus S. , King, Wendy C. , Kleiner, David Erwin

JAMA Network Open | April 10, 2023 | Volume: 6 | Issue: 4 | Pages: e237018

10.1001/jamanetworkopen.2023.7018 | PMID 37036707 Get It

ImportanceDisparities in treatment initiation may affect outcomes, but data on racially diverse populations with chronic hepatitis B virus (HBV) infection are limited.ObjectiveTo examine whether HBV treatment initiation and outcomes differ among racial groups.Design, Setting, and ParticipantsFrom January 14, 2011, to January 28, 2018, hepatitis B surface antigen—positive adults (age ≥18 years) not receiving anti-HBV therapy were enrolled and followed up at weeks 12, 24, and every 24 weeks thereafter in a multicenter longitudinal cohort study (Hepatitis B Research Network [HBRN] adult cohort study) conducted in North America. The last study visit and data collection were completed January 28, 2019. Data were analyzed from August 27, 2021, to August 25, 2022. All HBRN participants were included unless they had acute HBV, HIV, hepatitis C or D, less than 24-weeks of follow-up after enrollment, initiated treatment at or immediately after enrollment, or had unknown race.ExposuresParticipants had clinical and laboratory assessments and could receive anti-HBV treatment after enrollment.Main Outcomes and MeasuresHepatitis B virus treatment initiation and major adverse liver outcomes (hepatic decompensation, hepatocellular carcinoma, liver transplant, and death).ResultsOf 1550 participants, 193 (12%) were African American or Black, 1157 (75%) were Asian, 157 (10%) were White, and 43 (3%) were other races; 789 (51%) were women, and the median age was 41.2 (IQR, 32.9-51.6) years. Sociodemographic and virologic parameters differed between groups. During 5727 person-years of follow-up, 504 participants initiated treatment, with incidences of 4.8 per 100 person-years in African American or Black individuals, 9.9 per 100 person-years in Asian individuals, 6.6 per 100 person-years in White individuals, and 7.9 per 100 person-years in those of other races (P &amp;lt; .001). A lower proportion (14%) of African American or Black participants met treatment criteria compared with Asian (22%) and White (27%) individuals (P = .01). The cumulative probabilities of treatment initiation after meeting the criteria were not significantly different among racial groups (African American or Black, 0.45; Asian, 0.38; White, 0.40 at 48 weeks and African American or Black, 0.45; Asian, 0.51; White, 0.51 at 72 weeks; P = .68). The incidence of major adverse liver outcomes was 0.1 per 100 person-years and did not differ by race.Conclusions and RelevanceIn this observational study of chronic HBV, African American or Black participants were less likely than individuals of other races to meet treatment criteria, but among those who did, HBV treatment receipt did not differ significantly by race or socioeconomic factors. Not all eligible participants initiated treatment, but adverse liver outcomes were rare. These findings may not be generalizable to patients with chronic HBV receiving care in other settings.